Live Breaking News & Updates on Rebecca Luse

Stay updated with breaking news from Rebecca luse. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline

$158M Series B-2 Financing led by Deep Track Capital, with new participation from leading global biotechnology investors including RA Capital Management,. ....

Dave Licata , Vince Ruiz , Ribociclib Kisqali , Mark Alles , Palbociclib Ibrance , Dennis Slamon , Perceptive Xontogeny Venture Fund , Slamon Research Laboratory , Bristol Myers Squibb , Division Of Hematology Oncology , Roth Zabel , Crandon Law , David Geffen School Of Medicine , Deep Track Capital , Perceptive Advisors , Avidity Partners , Goldman Sachs Alternatives , Vertex Ventures , Moore Strategic Ventures , Blue Owl Healthcare Opportunities , Notch Ligand , Rebecca Luse , Deep Track , Board Member , Scientific Co Founder Dennis Slamon , Geffen School ,

Mariana Oncology Raises $175M in Series B Funding

The firm will use the proceeds to develop radiopharmaceuticals, including its lead candidate poised to enter clinical trials next year in small cell lung cancer. ....

United States , Geert Jan Mulder , Eli Lilly , Atlas Venture , Mariana Oncology , Deep Track Capital , Access Biotechnology , Nextech Invest , Surveyor Capital , Rebecca Luse ,

Mariana Oncology Raises USD175M in Series B Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time! ....

Geert Jan Mulder , Eli Lilly , Atlas Venture , Forbion Ventures Fund , Mariana Oncology , Deep Track Capital , Access Biotechnology , Nextech Invest , Surveyor Capital , Forbion Managing Partner Geert Jan Mulder , Rebecca Luse , Simon Read , Chief Executive Officer ,

Apogee Therapeutics Launches with $169 Million to Develop Potentially Best-in-Class Therapies for Immunological and Inflammatory Disorders

Oversubscribed $149M Series B financing co-led by new investors Deep Track Capital and RTW Investments, LP adds to Series A investment from founding investors. ....

New Zealand General , New Zealand , San Francisco , United States , Hussam Shaheen , Michael Henderson , Dunn Crutcher , Perceptive Xontogeny Ventures Fund , Drug Administration , Fidelity Management Research Company , Apogee Therapeutics , Deep Track Capital , Venrock Healthcare Capital Partners , Paragon Therapeutics , Chief Executive Officer , Chief Executive Officer Michael Henderson , Fidelity Management , Research Company , Investigational New Drug , Rebecca Luse , Deep Track , Senior Vice President ,